DC regimen resulted in a higher response rate but without improvement in median time to tumor progression or OS compared with D. D could be a reasonable front-line chemotherapy for patients who cannot tolerate cisplatin.

. The present study indicates that, in patients with ACC who have relapsed after 5-FU plus LV, the administration of irinotecan fractionated into two doses every 21 days yields a similar efficacy to, but a much lower incidence of toxicity than, the same total dose of irinotecan administered once every 21 days.

NCT01985724.

The authors regret that while Figure 2B correctly depicts the Kaplan-Meier estimates for overall survival, the Hazard Ratio has been erroneously calculated: the given HR>1 favors in reality 6-month treatment. For reasons of consistency with Figure 2A (so, HR>1 favoring 12-month treatment), the correct value would be HR¼0.69 (95% CI: 0.27e1.76, p¼0.441).The first sentence from the Results section should now read: Between June 2004 and May 2012, 493 patients were randomized to receive either 12-months or 6-monhts trastuzumab treatment. However, five patients withdrew their consent after randomization and seven were found to be HER2 negative on local retesting. Thus, 481 (98%) were eligible for the study, 241 and 240 in the 12-months and 6-months, respectively (Figure 1; CONSORT diagram of the study).This change is depicted in the new CONSORT diagram, below. The authors would like to apologise for any inconvenience caused.